U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H20ClN5O5
Molecular Weight 421.835
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SONEDENOSON

SMILES

NC1=NC(OCCC2=CC=C(Cl)C=C2)=NC3=C1N=CN3[C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O

InChI

InChIKey=WUCQGGOGHZRELS-LSCFUAHRSA-N
InChI=1S/C18H20ClN5O5/c19-10-3-1-9(2-4-10)5-6-28-18-22-15(20)12-16(23-18)24(8-21-12)17-14(27)13(26)11(7-25)29-17/h1-4,8,11,13-14,17,25-27H,5-7H2,(H2,20,22,23)/t11-,13-,14-,17-/m1/s1

HIDE SMILES / InChI

Molecular Formula C18H20ClN5O5
Molecular Weight 421.835
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Sonedenoson (MRE0094) is a topical adenosine A2A-receptor agonist which was under clinical development for the treatment of for diabetic foot ulcer. The compound was originally developed by New York University, and licensed to Medco Research (King Pharmaceuticals). King Pharmaceuticals was acquired by Pfizer in 2010. Sonedenoson has been in phase II clinical trials for the treatment of chronic diabetic neuropathic foot ulcers. However, this research has been discontinued.

Approval Year

PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Application of Sonedenoson (MRE0094) (1 ug/wound and 10 ug/wound) achieved 50% wound closure significantly more rapidly than control application (day 1.9, 1.9, 3.5, 3.2, respectively, versus control day 4).
Route of Administration: Topical
TSP1 protein secretion was down-regulated after treatment with the A2A agonist in a dose-dependent manner (EC50 = 0.23 uM).
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:31:31 GMT 2023
Edited
by admin
on Fri Dec 15 16:31:31 GMT 2023
Record UNII
2OT4KAG5JL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SONEDENOSON
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
ADENOSINE, 2-(2-(4-CHLOROPHENYL)ETHOXY)-
Systematic Name English
SONEDENOSON [USAN]
Common Name English
Sonedenoson [WHO-DD]
Common Name English
MRE0094
Code English
9-.BETA.-D-RIBOFURANOSYL-2-(2-(4-CHLOROPHENYL)ETHOXY)-9H-PURIN-6-AMINE
Common Name English
sonedenoson [INN]
Common Name English
MRE-0094
Code English
Classification Tree Code System Code
NCI_THESAURUS C29707
Created by admin on Fri Dec 15 16:31:31 GMT 2023 , Edited by admin on Fri Dec 15 16:31:31 GMT 2023
Code System Code Type Description
DRUG BANK
DB12443
Created by admin on Fri Dec 15 16:31:31 GMT 2023 , Edited by admin on Fri Dec 15 16:31:31 GMT 2023
PRIMARY
ChEMBL
CHEMBL1950553
Created by admin on Fri Dec 15 16:31:31 GMT 2023 , Edited by admin on Fri Dec 15 16:31:31 GMT 2023
PRIMARY
CAS
131865-88-8
Created by admin on Fri Dec 15 16:31:31 GMT 2023 , Edited by admin on Fri Dec 15 16:31:31 GMT 2023
PRIMARY
EPA CompTox
DTXSID90157239
Created by admin on Fri Dec 15 16:31:31 GMT 2023 , Edited by admin on Fri Dec 15 16:31:31 GMT 2023
PRIMARY
PUBCHEM
9910098
Created by admin on Fri Dec 15 16:31:31 GMT 2023 , Edited by admin on Fri Dec 15 16:31:31 GMT 2023
PRIMARY
USAN
TT-03
Created by admin on Fri Dec 15 16:31:31 GMT 2023 , Edited by admin on Fri Dec 15 16:31:31 GMT 2023
PRIMARY
INN
8928
Created by admin on Fri Dec 15 16:31:31 GMT 2023 , Edited by admin on Fri Dec 15 16:31:31 GMT 2023
PRIMARY
NCI_THESAURUS
C84176
Created by admin on Fri Dec 15 16:31:31 GMT 2023 , Edited by admin on Fri Dec 15 16:31:31 GMT 2023
PRIMARY
SMS_ID
300000034409
Created by admin on Fri Dec 15 16:31:31 GMT 2023 , Edited by admin on Fri Dec 15 16:31:31 GMT 2023
PRIMARY
FDA UNII
2OT4KAG5JL
Created by admin on Fri Dec 15 16:31:31 GMT 2023 , Edited by admin on Fri Dec 15 16:31:31 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> AGONIST
Related Record Type Details
ACTIVE MOIETY